Comparison of ezetimibe and atorvastatin treatment versus atorvastatin alone on Major Adverse Cardiac Events

Comparison of ezetimibe and atorvastatin treatment versus atorvastatin alone on Major Adverse Cardiac Events (MACE) after elective percutaneous coronary intervention (PCI)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171028037047N1

Enrollment

224

Registered

2018-06-22

Start date

2018-02-04

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: Patients in this group receive atorvastatin 40 mg and ezetimibe 10 mg daily. Intervention 2: Control group: Patients in this group receive atorvastatin 40 mg and pl

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are candidates for elective PCI Having normal hepatic enzymes Having negative troponin Having LDL values greater than 100 mg / dL

Exclusion criteria

Exclusion criteria: Having Inflammatory and rheumatologic diseases Having Infectious diseases Having malignancies Having high creatinine levels Having abnormal liver enzymes Pregnancy and lactation Use of NSAIDs Patient's dissatisfaction with participating in the study Having ejection fraction below 30 (EF < 30) Having myocardial infarction in the last month The increase in troponin after PCI more than 5 times higher than normal maximum of 99 percentile

Design outcomes

Primary

Measure	Time frame
Myocardial infarction. Timepoint: At intervals of 24 hours after PCI and one month after PCI. Method of measurement: ECG, hospital records, blood tests and imaging.	—

Secondary

Measure	Time frame
Unstable angina. Timepoint: At intervals of 24 hours after PCI and one month after PCI. Method of measurement: ECG, hospital records, blood tests and imaging.;Death rate due to heart disease. Timepoint: At intervals of 24 hours after PCI and one month after PCI. Method of measurement: Hospital records.;Stroke rate. Timepoint: At intervals of 24 hours after PCI and one month after PCI. Method of measurement: ECG, hospital records, blood tests and imaging.;Stent thrombosis. Timepoint: At intervals of 24 hours after PCI and one month after PCI. Method of measurement: ECG, hospital records, blood tests and imaging.;CRP value. Timepoint: At intervals of 24 hours after PCI and one month after PCI. Method of measurement: Blood tests.	—

Measure

Time frame

Unstable angina. Timepoint: At intervals of 24 hours after PCI and one month after PCI. Method of measurement: ECG, hospital records, blood tests and imaging.;Death rate due to heart disease. Timepoint: At intervals of 24 hours after PCI and one month after PCI. Method of measurement: Hospital records.;Stroke rate. Timepoint: At intervals of 24 hours after PCI and one month after PCI. Method of measurement: ECG, hospital records, blood tests and imaging.;Stent thrombosis. Timepoint: At intervals of 24 hours after PCI and one month after PCI. Method of measurement: ECG, hospital records, blood tests and imaging.;CRP value. Timepoint: At intervals of 24 hours after PCI and one month after PCI. Method of measurement: Blood tests.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShahin Abbas Zadeh

Bandare-abbas University of Medical Sciences

sh-abaszadeh@yahoo.com+98 76 3333 7379

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026